UPDATE: Piper Jaffray Raises Price Target on Trius Therapeutics to $15

According to Piper Jaffray, Trius Therapeutics

price target is raised to $15. Piper Jaffray said that following positive results from the 1st pivotal tedizolid trial, Trius is a Top Pick for 2012. “We reiterate our Overweight rating and are increasing our price target to $15 from $12.” Trius Therapeutics closed on Friday at $7.15.